Advertisement

Conotoxin Venom Peptide Therapeutics

  • Richard J. Lewis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 655)

Abstract

Venom peptides offer enormous opportunity for the discovery of peptide drug leads. This review focusses on the potential of cone snails that have developed arrays of small peptides as part of highly evolved venoms used for prey capture and defence. Many of these peptides selectively modulate ion channels and transporters, making them a valuable source of new ligands for studying the role these targets play in normal and disease physiology. A number of these conopeptides reduce pain in animals models and several are now in preclinical and clinical development for the treatment of severe pain often associated with diseases such as cancer.

Keywords

Cone Snail Calcium Channel Inhibitor Neuronal Calcium Channel Sodium Channel Inhibitor Sodium Channel Subtype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nature Reviews Drug Discovery 2003; 2:790–802.CrossRefPubMedGoogle Scholar
  2. 2.
    Lewis RJ, Nielsen KJ, Craik DJ et al. Novel ω-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000; 275:35335–35344.CrossRefPubMedGoogle Scholar
  3. 3.
    Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin, and hot-plate tests in rats. Pain 1995; 60:83–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith M, Cabot PJ, Ross FB et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002; 96:119–127.CrossRefPubMedGoogle Scholar
  5. 5.
    Nielsen K, Schroeder T, Lewis RJ. Structure-activity relationships of ω-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognition 2000; 13:55–70.CrossRefGoogle Scholar
  6. 6.
    Schroeder CI, Smythe ML, Lewis RJ. Development of small molecules that mimic the binding of ω-conotoxins at the N-type voltage-gated calcium channel. Molec Diversity 2004; 8:127–134.CrossRefGoogle Scholar
  7. 7.
    Wood JN, Boorman J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr Top Med Chem 2005; 5:529–537.CrossRefPubMedGoogle Scholar
  8. 8.
    Ekberg J, Jayamanne A, Vaughan CW et al. μO-conotoxin MrVIB selectively blocks Na, 1.8 sensory neuron specific sodium channels and chronic pain without motor deficits. Proc Natl Acad Sci 2006; 103:17030–17035.CrossRefPubMedGoogle Scholar
  9. 9.
    Nicke A, Wonnacott S, Lewis RJ. α-Conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes. Eur J Biochem 2004; 271:2305–2319.CrossRefPubMedGoogle Scholar
  10. 10.
    Sandall DW, Satkunanathan N, Keays DA et al. A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo Biochemistry 2003; 42:6904–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Sharpe IA, Gehrmann J, Loughnan ML et al. Two new classes of conopeptides inhibit the α1-adrenoceptor and noradrenaline transporter. Nature Neurosci 2001; 4:902–907.CrossRefPubMedGoogle Scholar
  12. 12.
    Nielsen CK, Lewis RJ, Alewood D et al. Anti-allodynic efficacy of the ξ-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005; 118:112–124.CrossRefPubMedGoogle Scholar
  13. 13.
    Paczkowski FA, Sharpe IA, Dutertre S et al. ξ-Conopeptide and tricyclic anti-depressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem 2007; 282:17837–17844.CrossRefPubMedGoogle Scholar
  14. 14.
    Malmberg AB, Gilbert H, McCabe RT et al. Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain 2003; 101:109–116.CrossRefPubMedGoogle Scholar
  15. 15.
    Craig AG, Norberg T, Griffin D et al. Contulakin-G, an O-glycosylated invertebrate neurotensin. J Biol Chem 1999; 274:13752–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Allen JW, Hofer K, McCumber D et al. An assessment of the antinociceptive efficacy of intrathecal and epidural contulakin-G in rats and dogs. Anesth Analg 2007; 104:1505–13.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Richard J. Lewis
    • 1
  1. 1.Xenome Ltd, Indooroopilly 4068 and Institute for Molecular BiosciencesThe University of QueenslandBrisbaneAustralia

Personalised recommendations